IP Library › Granted Patent US 12,258,596
Granted Patent B2
US 12,258,596 · App. 18/923,463 · Granted Mar 25, 2025

Polynucleotides encoding paraoxonase fusion polypeptides

Inventors: Jeffrey A. Ledbetter (Shoreline, WA); Martha S. Hayden-Ledbetter (Shoreline, WA)
Assignee: Theripion, Inc.
C12N9/22A61P11/00C07K16/241C12N9/16C12Y301/08001A61K38/00C07K2317/31C07K2317/622C07K2319/01C07K2319/30C12Y301/21001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,258,596
App. No.
18/923,463
Granted
Mar 25, 2025
Kind
B2
Abstract

Compositions and methods relating to paraoxonase fusion polypeptides are disclosed. In some aspects, the fusions are bispecific molecules that include a first biologically active polypeptide linked amino-terminal to a biologically active paraoxonase, wherein the first biologically active polypeptide is a DNase, an RNase, a SOD1, a CTLA-4 extracellular domain, a CD40 extracellular domain, or a polypeptide that specifically binds and neutralizes an inflammatory cytokine. Bispecific fusions may further include a second biologically active polypeptide (e.g., a dimerizing or FcRn-binding domain) linked carboxyl-terminal to the first biologically active polypeptide and amino-terminal to the paraoxonase. In other aspects, a fusion polypeptide includes a biologically active paraoxonase linked carboxyl-terminal or amino-terminal to a dimerizing or FcRn-binding domain. Also disclosed are dimeric proteins comprising first and second paraoxonase fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.

Claims (101)

1. A polynucleotide encoding a fusion polypeptide, wherein the fusion polypeptide comprises, from an amino terminal position to a carboxyl terminal position, T-L1-X-L2-P, wherein:

T is a first biologically active polypeptide selected from the group consisting of

a cytotoxic T-lymphocyte associated molecule-4 (CTLA-4) extracellular domain, and

a CD40 extracellular domain;

L1 is a first polypeptide linker, wherein L1 is optionally present;

X is an immunoglobulin heavy chain constant region, wherein the immunoglobulin heavy chain constant region is capable of forming dimers and specifically binding the neonatal Fc receptor (FcRn);

L2 is a second polypeptide linker comprising at least eight amino acid residues; and

P is a biologically active paraoxonase, wherein the paraoxonase has at least 95% identity with the amino acid sequence shown in residues 16-355 or 26-355 of SEQ ID NO:6, and wherein the paraoxonase does not contain an amino terminal leader sequence corresponding to residues 1-15 of SEQ ID NO:6;

wherein the fusion polypeptide comprises an amino acid sequence having at least 95% identity with the amino acid sequence shown in

(i) residues 21-736 of SEQ ID NO:66,

(ii) residues 21-804 of SEQ ID NO:74,

(iii) residues 21-804 of SEQ ID NO:78,

(iv) residues 21-804 of SEQ ID NO:82,

(v) residues 21-804 of SEQ ID NO:86, or

(vi) residues 21-804 of SEQ ID NO:90.

2. The polynucleotide of claim fusion polypeptide of claim 1 , wherein the immunoglobulin heavy chain constant region is a human immunoglobulin Fc region.

3. The polynucleotide of claim 1 , wherein the fusion polypeptide comprises the amino acid sequence shown in

(i) residues 21-736 of SEQ ID NO:66,

(ii) residues 21-804 of SEQ ID NO:74,

(iii) residues 21-804 of SEQ ID NO:78,

(iv) residues 21-804 of SEQ ID NO:82,

(v) residues 21-804 of SEQ ID NO:86, or

(vi) residues 21-804 of SEQ ID NO:90.

4. The polynucleotide of claim 1 , wherein the first biologically active polypeptide is the CTLA-4 extracellular domain.

5. The polynucleotide of claim 4 , wherein the CTLA-4 extracellular domain has at least 95% identity with the amino acid sequence shown in residues 21-144 of SEQ ID NO:66.

6. The polynucleotide of claim 5 , wherein the CTLA-4 extracellular domain has the amino acid sequence shown in residues 21-144 of SEQ ID NO:66.

7. The polynucleotide of claim 1 , wherein the first biologically active polypeptide is the CD40 extracellular domain.

8. The polynucleotide of claim 7 , wherein the CD40 extracellular domain has at least 95% identity with the amino acid sequence shown in

(i) residues 21-188 of SEQ ID NO:74,

(ii) residues 21-188 of SEQ ID NO:78,

(iii) residues 21-188 of SEQ ID NO:82,

(iv) residues 21-188 of SEQ ID NO:86, or

(v) residues 21-188 of SEQ ID NO:90.

9. The polynucleotide of claim 8 , wherein the CD40 extracellular domain contains at least one amino acid substitution at a position corresponding to an amino acid of human CD40 (SEQ ID NO:68) selected from the group consisting of E64, K81, P85, and L121, wherein the at least one amino acid substitution increases CD40 ligand binding relative to human CD40.

10. The polynucleotide of claim 9 , wherein

the amino acid at the position corresponding to K81 of human CD40 is selected from the group consisting of threonine, histidine, and serine;

the amino acid at the position corresponding to K81 of human CD40 is histidine and the amino acid the position corresponding to L121 of human CD40 is proline; or

the amino acid at the position corresponding to E64 of human CD40 is tyrosine, the amino acid at the position corresponding to K81 of human CD40 is threonine, and the amino acid at the position corresponding to P85 of human CD40 is tyrosine.

11. The polynucleotide of claim 8 , wherein the CD40 extracellular domain has the amino acid sequence shown in

(i) residues 21-188 of SEQ ID NO:74,

(ii) residues 21-188 of SEQ ID NO:78,

(iii) residues 21-188 of SEQ ID NO:82,

(iv) residues 21-188 of SEQ ID NO:86, or

(v) residues 21-188 of SEQ ID NO:90.

12. A polynucleotide encoding a fusion polypeptide, wherein the fusion polypeptide comprises, from an amino terminal position to a carboxyl terminal position, T-L1-X-L2-P, wherein:

T is a single-chain antibody that specifically binds and neutralizes tumor necrosis factor α (TNFα), wherein the single-chain antibody is a single-chain Fv (scFv);

L1 is a first polypeptide linker, wherein L1 is optionally present;

X is an immunoglobulin heavy chain constant region, wherein the immunoglobulin heavy chain constant region is capable of forming dimers and specifically binding the neonatal Fc receptor (FcRn);

L2 is a second polypeptide linker comprising at least eight amino acid residues; and

P is a biologically active paraoxonase, wherein the paraoxonase has at least 95% identity with the amino acid sequence shown in residues 16-355 or 26-355 of SEQ ID NO:6, and wherein the paraoxonase does not contain an amino terminal leader sequence corresponding to residues 1-15 of SEQ ID NO:6;

wherein the single-chain antibody comprises a VH domain comprising complementarity determining regions (CDRs) CDR-H1 TNFα , CDR-H2 TNFα , and CDR-H3 TNFα , wherein CDR-H1 TNFα , CDR-H2 TNFα , and CDR-H3 TNFα are VH CDRs of SEQ ID NO:108;

wherein the single-chain antibody comprises a VL domain comprising complementarity determining regions (CDRs) CDR-L1 TNFα , CDR-L2 TNFα , and CDR-L3 TNFα , wherein CDR-L1 TNFα , CDR-L2 TNFα , and CDR-L3 TNFα are VL CDRs of SEQ ID NO:110; and

wherein the fusion polypeptide comprises an amino acid sequence having at least 95% identity with the amino acid sequence shown in

(i) residues 21-860 of SEQ ID NO:94, or

(ii) residues 21-860 of SEQ ID NO:98.

13. The polynucleotide of claim 12 , wherein the single-chain Fv (scFv) comprises a VH domain having at least 95% identity with the amino acid sequence shown in SEQ ID NO:108, and/or wherein the single-chain antibody comprises a VL domain having at least 95% identity with the amino acid sequence shown in SEQ ID NO:110.

14. The polynucleotide of claim 12 , wherein the single-chain Fv (scFV) has at least 95% identity with the amino acid sequence shown in

(i) residues 21-268 of SEQ ID NO:92, or

(ii) residues 21-268 of SEQ ID NO:96.

15. The polynucleotide of claim 14 , wherein the single-chain Fv (scFV) has the amino acid sequence shown in

(i) residues 21-268 of SEQ ID NO:92, or

(ii) residues 21-268 of SEQ ID NO:96.

16. The polynucleotide of claim 12 , wherein the fusion polypeptide comprises the amino acid sequence shown in

(i) residues 21-860 of SEQ ID NO:94, or

(ii) residues 21-860 of SEQ ID NO:98.

17. An expression cassette comprising a DNA segment encoding a fusion polypeptide, wherein the DNA segment is operably linked to a promoter, and wherein the fusion polypeptide comprises, from an amino terminal position to a carboxyl terminal position, T-L1-X-L2-P, wherein:

T is a first biologically active polypeptide selected from the group consisting of

a cytotoxic T-lymphocyte associated molecule-4 (CTLA-4) extracellular domain, and

a CD40 extracellular domain;

L1 is a first polypeptide linker, wherein L1 is optionally present;

X is an immunoglobulin heavy chain constant region, wherein the immunoglobulin heavy chain constant region is capable of forming dimers and specifically binding the neonatal Fc receptor (FcRn);

L2 is a second polypeptide linker comprising at least eight amino acid residues; and

P is a biologically active paraoxonase, wherein the paraoxonase has at least 95% identity with the amino acid sequence shown in residues 16-355 or 26-355 of SEQ ID NO:6, and wherein the paraoxonase does not contain an amino terminal leader sequence corresponding to residues 1-15 of SEQ ID NO:6;

wherein the fusion polypeptide comprises an amino acid sequence having at least 95% identity with the amino acid sequence shown in

(i) residues 21-736 of SEQ ID NO:66,

(ii) residues 21-804 of SEQ ID NO:74,

(iii) residues 21-804 of SEQ ID NO:78,

(iv) residues 21-804 of SEQ ID NO:82,

(v) residues 21-804 of SEQ ID NO:86, or

(vi) residues 21-804 of SEQ ID NO:90.

18. A cultured cell into which has been introduced the expression cassette of claim 17 , wherein the cell expresses the DNA segment.

19. A method of making a fusion polypeptide, the method comprising:

culturing a cell into which has been introduced the expression cassette of claim 17 , wherein the cell expresses the DNA segment and the encoded fusion polypeptide is produced; and

recovering the fusion polypeptide.

20. The method of claim 19 , wherein the encoded fusion polypeptide is produced and recovered as a dimeric protein.

21. An expression cassette comprising a DNA segment encoding a fusion polypeptide, wherein the DNA segment is operably linked to a promoter, and wherein the fusion polypeptide comprises, from an amino terminal position to a carboxyl terminal position, T-L1-X-L2-P, wherein:

T is a single-chain antibody that specifically binds and neutralizes tumor necrosis factor α (TNFα), wherein the single-chain antibody is a single-chain Fv (scFv);

L1 is a first polypeptide linker, wherein L1 is optionally present;

X is an immunoglobulin heavy chain constant region, wherein the immunoglobulin heavy chain constant region is capable of forming dimers and specifically binding the neonatal Fc receptor (FcRn);

L2 is a second polypeptide linker comprising at least eight amino acid residues; and

P is a biologically active paraoxonase, wherein the paraoxonase has at least 95% identity with the amino acid sequence shown in residues 16-355 or 26-355 of SEQ ID NO:6, and wherein the paraoxonase does not contain an amino terminal leader sequence corresponding to residues 1-15 of SEQ ID NO:6;

wherein the single-chain antibody comprises a VH domain comprising complementarity determining regions (CDRs) CDR-H1 TNFα , CDR-H2 TNFα , and CDR-H3 TNFα , wherein CDR-H1 TNFα , CDR-H2 TNFα , and CDR-H3 TNFα are VH CDRs of SEQ ID NO:108;

wherein the single-chain antibody comprises a VL domain comprising complementarity determining regions (CDRs) CDR-L1 TNFα , CDR-L2 TNFα , and CDR-L3 TNFα , wherein CDR-L1 TNFα , CDR-L2 TNFα , and CDR-L3 TNFα are VL CDRs of SEQ ID NO:110; and

wherein the fusion polypeptide comprises an amino acid sequence having at least 95% identity with the amino acid sequence shown in

(i) residues 21-860 of SEQ ID NO:94, or

(ii) residues 21-860 of SEQ ID NO:98.

22. A cultured cell into which has been introduced the expression cassette of claim 21 , wherein the cell expresses the DNA segment.

23. A method of making a fusion polypeptide, the method comprising:

culturing a cell into which has been introduced the expression cassette of claim 21 , wherein the cell expresses the DNA segment and the encoded fusion polypeptide is produced; and

recovering the fusion polypeptide.

24. The method of claim 23 , wherein the encoded fusion polypeptide is produced and recovered as a dimeric protein.

Continuity (4)
Division 18546413
Provisional Application 63151272 · Feb 19, 2021
Provisional Application 63151236 · Feb 19, 2021
Related Publication 20250059525A1 · Feb 20, 2025
References Cited (126)
US 8735124B2 · Tawfik · 2014 [cited by applicant]
US 20030092059A1 · Salfeld et al. · 2003 [cited by applicant]
US 20030118592A1 · Ledbetter et al. · 2003 [cited by applicant]
US 20100098693A1 · Pardridge · 2010 [cited by applicant]
US 20120213834A1 · Tawfik et al. · 2012 [cited by applicant]
US 20140120091A1 · Ledbetter et al. · 2014 [cited by applicant]
US 20180201664A1 · Hayden-Ledbetter · 2018 [cited by applicant]
US 20190241878A1 · Posada et al. · 2019 [cited by applicant]
US 20240101982A1 · Ledbetter · 2024 [cited by examiner]
WO 2011084714A2 · 2011 [cited by applicant]
WO 2014115084A2 · 2014 [cited by applicant]
WO 2018136163A2 · 2018 [cited by applicant]
WO WO2022178078A9 · 2022 [cited by examiner]
Propst, S.M., et al., “Proinflammatory and Th2-Derived Cytokines Modulate CD40-Mediated Expression of Inflammatory Mediators in Airway Epithelia: Implications for the Role of Epithelial CD40 in Airway Inflammation,” J. … [cited by applicant]
Rothem, L., et al., “Paraoxonases are associated with intestinal inflammatory diseases and intracellularly localized to the endoplasmic reticulum,” Free Radic. Biol. Med. 43:730-739, 2007. [cited by applicant]
Seo, D., et al., “The Paraoxonase Gene Family and Atherosclerosis,” Curr. Atheroscler. Rep. 11:182-187, 2009. [cited by applicant]
Sime, P.J., et al., “Fibrosis of the Lung and Other Tissues: New Concepts in Pathogenesis and Treatment,” Clin. Immunol. 99:308-319, Jun. 2001. [cited by applicant]
You, Y., et al., “Effect of N-acetylcysteine on the Murine Model of Colitis Induced by Dextran Sodium Sulfate Through Up-Regulating PON1 Activity,” Dig. Dis. Sci. 54:1643-1650, 2009, DOI:10.1007/s10620-008-0563-9. [cited by applicant]
Zhang, Y., et al., “CD40 Engagement Up-Regulates Cyclooxygenase-2 Expression and Prostaglandin E2 Production in Human Lung Fibroblasts,” J. Immunol. 160:1053-1057, 1990. [cited by applicant]
GenBank Accession No. MF101816.1, Synthetic construct long-acting recombinant human paraoxonase 1 (G4Fc-L2-rhPON1) gene, complete cds, submitted May 15, 2017. [cited by applicant]
GenBank Accession No. MF101815.1, Synthetic construct long-acting recombinant human paraoxonase 1 (G4Fc-L1-rhPON1) gene, complete cds, submitted May 15, 2017. [cited by applicant]
GenBank Accession No. MF101814.1, Synthetic construct long-acting recombinant human paraoxonase 1 (G2Fc-L2-rhPON1) gene, complete cds, submitted May 15, 2017. [cited by applicant]
GenBank Accession No. MF101813.1, Synthetic construct long-acting recombinant human paraoxonase 1 (G2Fc-L1-rhPON1) gene, complete cds, submitted May 15, 2017. [cited by applicant]
GenBank Accession No. MF101812.1, Synthetic construct long-acting recombinant human paraoxonase 1 (rhPON1) gene, complete cds, submitted May 15, 2017. [cited by applicant]
Sequence Listing submitted with International Application No. PCT/IB2014/058461, filed Jan. 22, 2014 (published Jul. 31, 2014, as International Publication No. WO 2014/115084 A2). [cited by applicant]
Chen, W.-Q., et al., “Influences of PON1 on airway inflammation and remodeling in bronchial asthma,” J. Cell. Biochem. 119:793-805, 2018. [cited by applicant]
Dahl, M., et al., “Protection against inhaled oxidants through scavenging of oxidized lipids by macrophage receptors MARCO and SR-AI/II,” J. Clin. Invest. 117:757-764, 2007, DOI:10.1172/JCI29968. [cited by applicant]
Emin, O., et al., “Plasma paraoxonase, oxidative status level, and their relationship with asthma control test in children with asthma,” Allergol. Immunopathol. (Madr). 43:346-352, 2015. [cited by applicant]
Fellner, R.C., et al., “Inhaled protein/peptide-based therapies for respiratory disease,” Mol. Cell. Pediatr. 3:16, pp. 1-5, 2016, DOI:10.1186/s40348-016-0044-8. [cited by applicant]
Fessler, M.B., et al., “A New Frontier in Immunometabolism: Cholesterol in Lung Health and Disease,” Ann. Am. Thorac. Soc. 14:S399-S405, Nov. 2017. [cited by applicant]
Gaidudkov, L., et al., “In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes,” BMC Clin. Pharmacol. 9:18, Nov. 17, 2009, DOI:10.1186/1472-6904-9-18. [cited by applicant]
Gallego, M., et al., “Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors,” BMC Pulm. Med. 14:103, pp. 1-12, 2014. [cited by applicant]
Golmanesh, L., et al., “Simple procedures for purification and stabilization of human serum paraoxonase-1,” J. Biochem. Biophys. Methods 70, 1037-1042, 2008. [cited by applicant]
Golmanesh, L., et al., “Assessing the relationship of paraoxonase-1 Q192R polymorphisms and the severity of lung disease in SM-exposed patients,” Immunopharmacol. Immunotoxicol. 35:419-425, 2013. [cited by applicant]
Gu, X., et al., “Identification of critical paraoxonase 1 residues involved in high density lipoprotein interaction,” J. Biol. Chem. Manuscript M115.678334, Nov. 13, 2015. [cited by applicant]
Gupta, R.D., et al., “Directed evolution of hydrolases for prevention of G-type nerve agent intoxication,” Nat. Chem. Biol. 7:120-125, Jan. 9, 2010, DOI:10.1038/NCHEMBIO.510. [cited by applicant]
Harel, M., et al., “Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes,” Nat. Struct. Mol. Biol. 11:412-419, May 2004. [cited by applicant]
Hraiech, S., et al., “Inhaled Lactonase Reduces Pseudomonas aeruginosa Quorum Sensing and Mortality in Rat Pneumonia,” 9:e107125, pp. 1-8, Oct. 2014. [cited by applicant]
Huang, Y., et al., “Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex,” J. Clin. Invest. 123:3815-3828, Sep. 2013. [cited by applicant]
Ivanisevic, J., et al., “Association of serum amyloid A and oxidative stress with paraoxonase 1 in sarcoidosis patients,” Eur. J. Clin. Invest. 46:418-424, 2016. [cited by applicant]
Litvinov, D., et al., “Antioxidant and Anti-Inflammatory Role of Paraoxonase 1: Implication in Arteriosclerosis Diseases,” N. Am. J. Med. Sci. 4:523-532, Nov. 2012. [cited by applicant]
Mulcahy, L.R., et al., “Pseudomonas aeruginosa biofilms in disease,” Microb. Ecol. 68:1-12, Jul. 2014, DOI:10.1007/s00248-013-0297-x. [cited by applicant]
Murugayah, S.A., and Gerth, M.L., “Engineering quorum quenching enzymes: progress and perspectives” Biochem. Soc. Trans. 47:793-800, 2019. [cited by applicant]
Okur, H.K., et al., “Lipid peroxidation and paraoxonase activity in nocturnal cyclic and sustained intermittent hypoxia,” Sleep Breath. 17:365-371, 2013, DOI:10.1007/s11325-012-0703-5. [cited by applicant]
Rahman, I., et al., “Antioxidant therapies in COPD,” Int. J. Chron. Obstruct. Pulmon. Dis. 1(1):15-29, 2006. [cited by applicant]
Rahman, I., et al., “Pharmacological Antioxidant Strategies as Therapeutic Interventions for COPD,” Biochim. Biophys. Acta 1822:714-728, May 2012. [cited by applicant]
Rajkovic, M.G., “PON1 gene polymorphisms in patients with chronic obstructive pulmonary disease,” J. Clin. Pathol. 71:963-970, 2018, DOI:10.1136/jclinpath-2018-205194 963. [cited by applicant]
Rosenblat, M., et al., “Paraoxonase 1 (PON1) inhibits monocyte-to-macrophage differentiation,” Atherosclerosis 219:49-56, 2011. [cited by applicant]
Rumora, L., et al., “Paraoxonase 1 Activity in Patients with Chronic Obstructive Pulmonary Disease,” COPD, 11:539-545, 2014. [cited by applicant]
Sahiner, U.M., et al., “Oxidative Stress in Asthma,” World Allergy Organ. J. 4:151-158, 2011. [cited by applicant]
Sarioglu, N., et al., “Paraoxonase 1 Phenotype and Paraoxonase Activity in Asthmatic Patients,” Iran J. Allergy Asthma Immunol. 14:60-66, Feb. 2015. [cited by applicant]
Szczeklik, K., et al., “Correlation of Paraoxonase-1 with the Severity of Crohn's Disease,” Molecules 23:2603, pp. 1-15, 2018. [cited by applicant]
Tang, K., et al., “MomL, a Novel Marine-Derived N-Acyl Homoserine Lactonase from Muricauda olearia,” Appl. Environ. Microbiol. 81:774-782, Jan. 2015. [cited by applicant]
Tolgyesi, G., et al., “Gene expression profiling of experimental asthma reveals a possible role of paraoxonase-1 in the disease,” Int. Immunol. 21:967-975, Jun. 25, 2009. [cited by applicant]
Uzun, H., et al., “Levels of paraoxonase, an index of antioxidant defense, in patients with active sarcoidosis,” Curr. Med. Res. Opin. 24:1651-1657, 2008. [cited by applicant]
Valiyaveettil, M., et al., “Protective efficacy of catalytic bioscavenger, paraoxonase 1 against sarin and soman exposure in guinea pigs,” Biochem. Pharmacol. 81:800-809, 2011. [cited by applicant]
Valiyaveettil, M., et al., “Recombinant paraoxonase 1 protects against sarin and soman toxicity following microinstillation inhalation exposure in guinea pigs,” Toxicol. Lett. 202:203-208, 2011. [cited by applicant]
Adawi, A., et al., “Disruption of the CD40-CD40 Ligand System Prevents an Oxygen-Induced Respiratory Distress Syndrome,” Am. J. Pathol. 152:651-657, Mar. 1998. [cited by applicant]
Adawi, A., et al., “Blockade of CD40-CD40 Ligand Interactions Protects against Radiation-Induced Pulmonary Inflammation and Fibrosis,” Clin. Immunol. Immunopathol. 89:222-230, Dec. 1998. [cited by applicant]
Aybey, A., and Demirkan, E., “Inhibition of quorum sensing-controlled virulence factors in Pseudomonas aeruginosa by human serum paraoxonase,” J. Med. Microbiol. 65:105-113, 2016. [cited by applicant]
Billecke, S., et al., Human Serum Paraoxonase (PON1) Isozymes Q and R Hydrolyze Lactones and Cyclic Carbonate Esters, Drug Metab. Dispos. 28:1335-1342, 2000. [cited by applicant]
Boleto, G., et al., “T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis,” Arthritis Res. Ther. 20:197, pp. 1-12, 2018. [cited by applicant]
Carreno, B.M., et al., “CTLA-4 (CD152) Can Inhibit T Cell Activation by Two Different Mechanisms Depending on Its Level of Cell Surface Expression,” J. Immunol. 165:1352-1356, 2000. [cited by applicant]
Cheng, W., et al., “CXXC5 Attenuates Pulmonary Fibrosis in a Bleomycin-Induced Mouse Model and MLFs by Suppression of the CD40/CD40L Pathway,” BioMed. Res. Int., vol. 2020, Article ID 7840652, pp. 1-15, 2020. [cited by applicant]
Gaidukov, L., and Tawfik, D.S., “The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity,” J. Lipid Res. 48:1637-1646, 2007. [cited by applicant]
Kaufman, J., et al., “Expression of CD154 (CD40 Ligand) by Human Lung Fibroblasts: Differential Regulation by IFN-gamma and IL-13, and Implications for Fibrosis,” J. Immunol. 172:1862-1871, 2004. [cited by applicant]
Kheronsky, O., and Tawfik, D.S., “Structure-Reactivity Studies of Serum Paraoxonase PON1 Suggest that Its Native Activity Is Lactonase,” Biochem. 44:6371-6382, 2005. [cited by applicant]
Linsley, P.S., et al., “CTLA-4 Is a Second Receptor for the B Cell Activation Antigen B7,” J. Exp. Med. 174:561-569, Sep. 1991. [cited by applicant]
Liu, Z., et al., “Prevention of Experimental Colitis in SCID Mice Reconstituted with CD45RBhigh CD4+ T Cells by Blocking the CD40-CD154 Interactions,” J. Immunol. 164:6005-6014, 2000. [cited by applicant]
Martinez-Solano, L., et al., “Chronic Pseudomonas aeruginosa Infection in Chronic Obstructive Pulmonary Disease,” Clin. Infect. Dis. 47:1526-1533, 2008. [cited by applicant]
Mayer-Hamblett, N., et al., “Pseudomonas aeruginosa Phenotypes Associated With Eradication Failure in Children With Cystic Fibrosis,” Clin. Infect. Dis. 59:624-631, 2014. [cited by applicant]
Miller, Y.I., et al., “Context-dependent role of oxidized lipids and lipoproteins in inflammation,” Trends Endocrinol. Metab. 28:143-152, Feb. 2017, DOI:10.1016/j.tem.2016.11.002. [cited by applicant]
Nolan, A., et al., “CD40 and CD80/86 Act Synergistically to Regulate Inflammation and Mortality in Polymicrobial Sepsis,” Am. J. Respir. Crit. Care Med. 177:301-308, 2008. [cited by applicant]
Oran, M., et al., “Evaluation of Paraoxonase and Arylesterase activities in patients with irritable bowel syndrome,” J. Pak. Med. Assoc. 64:820-822, Jul. 2014. [cited by applicant]
Ponsoye, M., et al., “Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis,” Ann. Rheum. Dis. 75:2142-2149, 2016. [cited by applicant]
Gaidukov, L., et al., “High Affinity, Stability, and Lactonase Activity of Serum Paraoxonase PON1 Anchored on HDL with ApoA-I,” Biochemistry 2005, 44: 11843-11854. [cited by applicant]
International Search Report & Written Opinion mailed Sep. 29, 2022, issued in corresponding International Application No. PCT/US2022/016723, filed Feb. 17, 2022, 20 pages. [cited by applicant]
Aharoni, A., et al., “Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization,” Proc. Natl. Acad. Sci. USA 101:482-487, Jan. 13, 2004, DOI:10.1073/pnas.2536901100. [cited by applicant]
Goldsmith, M., et al., “Evolved Stereoselective Hydrolases for Broad-Spectrum G-Type Nerve Agent Detoxification,” Chemistry & Biology 19:456-466, Apr. 20, 2012. [cited by applicant]
Harel, M., et al., “3-D Structure of Serum Paraoxonase 1 Sheds Light On Its Activity, Stability, Solubility and Crystallizability,” Arh. Hig. Rada. Toksikol. 58:347-353, 2007. [cited by applicant]
Sarkar, M., et al., “Solubilization and Humanization of Paraoxonase-1,” J. Lipids, vol. 2012, Article ID Article ID 610937, pp. 1-13, 2012, DOI:10.1155/2012/610937. [cited by applicant]
Shiokawa, D., et al., “Identification of two functional nuclear localization signals in DNase γ and their roles in its apoptotic DNase activity,” Biochem. J. 376:377-381, 2003. [cited by applicant]
Zharkova, O., et al., “A Flow Cytometry-Based Assay for High-Throughput Detection and Quantification of Neutrophil Extracellular Traps in Mixed Cell Populations,” Cytometry Part A 95A:268-278, 2019. [cited by applicant]
Sorenson, R.C., et al., “Human Serum Paraoxonase/Arylesterase's Retained Hydrophobic N-Terminal Leader Sequence Associates with HDLs by Binding Phospholipids—Apolipoprotein A-I Stabilizes Activity,” Arterioscler. Thromb… [cited by applicant]
Stoltz, D.A., et al., “ [cited by applicant]
Bacchetti, T., et al., “Plasma oxidation status and antioxidant capacity in psoriatic children,” Arch. Dermatol. Res. 312:33-39, 2020. [cited by applicant]
Shakoei, S., et al., “The Serum Level of Oxidative Stress and Antioxidant Markers in Patients with Psoriasis: A Cross-sectional Study,” J. Clin. Aesthet. Dermatol. 14:38-41, 2021. [cited by applicant]
Simonetti, O., et al., “Oxidative Stress and Alterations of Paraoxonases in Atopic Dermatitis,” Antioxidants 10:697, pp. 1-11, 2021. [cited by applicant]
Boado, R.J., et al., “IgG-Paraoxonase-1 Fusion Protein for Targeted Drug Delivery Across the Human Blood-Brain Barrier,” Mol. Pharm. 5:1037-1043, 2008. [cited by applicant]
Lee, S.J., et al., “PEP-1-paraoxonase 1 fusion protein prevents cytokine-induced cell destruction and impaired insulin secretion in rat insulinoma cells,” BMB Rep. 51:538-543, 2018. [cited by applicant]
Kim, D.S., et al. “Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease,” Pharmacogenomics Author Manuscript; available in PMC Jul. 1, 2014; published in final edited for… [cited by applicant]
Stevens, R.C., et al., “Engineered recombinants human paraoxonase 1 (rHuPON1) purified from [cited by applicant]
Eren, E., et al., “Functionally Defective High-Density Lipoprotein and Paraoxonase: A Couple for Endothelial Dysfunction in Atherosclerosis,” Cholesterol, vol. 2013, Article ID 792090, 2013 DOI:10.1155/2013/792090. [cited by applicant]
Kim, M.J., et al., “Transduced PEP-1-PON1 proteins regulate microglial activation and dopaminergic neuronal death in a Parkinson's disease model,” Biomaterials 64:45-56, 2015, available online Jun. 14, 2015. [cited by applicant]
Koren-Gluzer, M., et al., “The antioxidant HDL-associated paraoxonase-1 (PON1) attenuates diabetes development and stimulates B-cell insulin release,” Atherosclerosis 219:510-518, 2011, available online Aug. 4, 2011, DO… [cited by applicant]
Mackness, M., et al., “Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles,” Gene 567:12-21, 2015, available online May 9, 2015, DOI:10.1016/j.gene.2015.04.… [cited by applicant]
Menini, T., et al., “Paraoxonase 1 in neurological disorders,” Redox Report, 19:49-58, 2014, DOI:10.1179/1351000213Y.0000000071. [cited by applicant]
Peng, W., et al., “Comparative evaluation of the protective potentials of human paraoxonase 1 and 3 against CCI4-induced liver injury,” Toxicol. Lett. 193:159-166, 2010, available online Jan. 15, 2010, DOI:10.1016/j.tox… [cited by applicant]
Rosenblat, M., et al., “Injection of paraoxonase 1 (PON1) to mice stimulates their HDL and macrophage antiatherogenicity,” Biofactors 37:462-467, 2011, published online Dec. 8, 2011, DOI:10.1002/biof.188. [cited by applicant]
Ceron, J.J., et al., “Serum paraoxonase 1 (PON1) measurement: an update,” BMC Vet. Res. 10:74, 2014, DOI:10.1186/1746-6148-10-74. [cited by applicant]
Dias, C.G., et al., “Quantification of the arylesterase activity of paraoxonase-1 in human blood,” Anal. Methods 6:289-294, 2014, DOI:10.1039/c3ay41527a. [cited by applicant]
Gugliucci, A., et al., “Enzymatic assessment of paraoxonase 1 activity on HDL subclasses: A practical zymogram method to assess HDL function,” Clin. Chim. Acta 415:162-168, 2013; available online Oct. 30, 2012; DOI:10.1… [cited by applicant]
Kirby, S.D., et al., “Human paraoxonase double mutants hydrolyze V and G class organophosphorus nerve agents,” Chem. Biol. Interact. 203:181-185, 2013; available online Nov. 15, 2012; DOI:10.1016/j.cbi.2012.10.023. [cited by applicant]
Otto, T.C., et al., “Dramatic Differences in Organophosphorus Hydrolase Activity between Human and Chimeric Recombinant Mammalian Paraoxonase-1 Enzymes,” Biochemistry 48:10416-10422, 2009, DOI:10.1021/bi901161b. [cited by applicant]
Yamashita, J., et al., Paraoxonase-1 Suppresses Experimental Colitis via the Inhibition of IFN-gamma Production from CD4 T Cells, J. Immunol. 191:949-960, 2013; prepublished Jun. 14, 2013; DOI:10.4049/jimmunol.1201828. [cited by applicant]
Bojic, S., et al., “Low Paraoxonase 1 Activity Predicts Mortality in Surgical Patients with Sepsis,” Disease Markers, vol. 2014, Article ID 427378, pp. 1-8, Feb. 9, 2014, DOI:10.1155/2014/427378. [cited by applicant]
Inal, V., et al., “Paraoxonase 1 Activity and Survival in Sepsis Patients,” Balkan Med. J. 32: 183-8, Apr. 2015, DOI:10.5152/balkanmedj.2015.15674. [cited by applicant]
Boado, R.J., et al., “CHO Cell Expression, Long-Term Stability, and Primate Pharmacokinetics and Brain Uptake of an IgG-Paraoxonase-1 Fusion Protein,” Biotechnol. Bioeng. 108:186-196, Jan. 1, 2011; published online Aug.… [cited by applicant]
Wang, X., et al., “IgG Fc engineering to modulate antibody effector functions,” Protein Cell 9:63-73, 2018, DOI:10.1007/s13238-017-0473-8. [cited by applicant]
Bitonti, A.J., et al., “Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway,” Proc. Natl. Acad. Sci. USA 101:9763-9768, Jun. 29, 2004. [cited by applicant]
Bitonti, A.J., et al., “Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway,” Adv. Drug Deliv. Rev. 58:1106-1118, 2006. [cited by applicant]
Hajri, T., “Effects of oxidized lipids and lipoproteins on cardiac function,” Front. Biosci. (Landmark Ed) 23:1822-1847, Jun. 1, 2018. [cited by applicant]
Hertel, S.P., et al., “Protein stability in pulmonary drug delivery via nebulization,” Adv. Drug Deliv. Rev. 93:79-94, 2015, available online Oct. 12, 2014. [cited by applicant]
Lo, M., et al., “Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice,” J. Biol. Chem. 292:3900-3908, Mar. 3, 2017. [cited by applicant]
Moldogazieva, N.T., et al., “Oxidative Stress and Advanced Lipoxidation and Glycation End Products (ALEs and AGEs) in Aging and Age-Related Diseases,” Oxid. Med. Cell. Longev., vol. 2019, Article ID 3085756, Aug. 14, 20… [cited by applicant]
Padlan, E.A., “Anatomy of the Antibody Molecule,” Mol. Immunol. 31:169-217, 1994. [cited by applicant]
Tam, S.H., et al., “Functional, Biophysical, and Structural Characterization of Human IgG1 and IgG4 Fc Variants with Ablated Immune Functionality,” Antibodies 6:12, 2017, DOI:10.3390/antib6030012. [cited by applicant]
Vallee, S., et al., “Pulmonary Administration of Interferon Beta-1a-Fc Fusion Protein in Non-Human Primates Using an Immunoglobulin Transport Pathway,” J. Interferon Cytokine Res. 32:178-184, 2012, DOI:10.1089/jir.2011.… [cited by applicant]
Bajaj, P., et al., “Characterization of human paraoxonase 1 variants suggest that His residues at 115 and 134 positions are not always needed for the lactonase/arylesterase activities of the enzyme,” Protein Sci. 22:179… [cited by applicant]
Bajaj, P., et al., “Expression and purification of biologically active recombinant human paraoxonase 1 from inclusion bodies of [cited by applicant]
Aalbers, F.S., and Fraaije, M.W., “Enzyme Fusions in Biocatalysis: Coupling Reactions by Pairing Enzymes,” ChemBioChem 20:20-28, 2019, DOI:10.1002/cbic.201800394. [cited by applicant]
Aviram, M., et al., “Paraoxonase Inhibits High-density Lipoprotein Oxidation and Preserves its Functions: A Possible Peroxidative Role for Paraoxonase,” J. Clin. Invest. 101:1581-1590, 1998. [cited by applicant]
Bajaj, P., et al., “Refolded Recombinant Human Paraoxonase 1 Variant Exhibits Prophylactic Activity Against Organophosphate Poisoning,” Appl. Biochem. Biotechnol. 180:165-176, 2016. [cited by applicant]
Bergonzi, C., et al., “The quorum-quenching lactonase from Geobacillus caldoxylosilyticus: purification, characterization, crystallization and crystallographic analysis,” Acta Cryst. F72:681-686, 2016. [cited by applicant]
Bergonzi, C., et al., “Structural and Biochemical Characterization of AaL, a Quorum Quenching Lactonase with Unusual Kinetic Properties,” Nature 8:11262, 2018, DOI:10.1038/s41598-018-28988-5. [cited by applicant]
Chen, X., et al., “Fusion Protein Linkers: Property, Design and Functionality,” Adv. Drug Deliv. Rev. 65:1357-1369, Oct. 15, 2013, DOI:10.1016/j.addr.2012.09.039. [cited by applicant]